Allergy drugs ‘out of stock’
CHILDREN with severe allergies face difficulties with treatment as a popular medicine has been declared “out of stock” amid an ongoing shortage.
EpiPen and EpiPen Junior devices, supplied by Mylan and produced by Pfizer, have faced shortages in the UK and other countries for months, but the Junior version is now unavailable.
A statement issued to healthcare providers on behalf of the Department of Health noted: “EpiPen and EpiPen Junior will be subject to limited availability for the remainder of 2018.”
More of the Junior devices are expected in stock in October, but it is not clear whether these will meet demand.
EpiPens are the most common adrenaline autoinjector devices and are issued to people who suffer from serious allergies. Users are being advised they can use their devices up to four months beyond the listed expiry date.